Internal Medicine | Page 119 of 487 | Links Medicus Content Curation & Alerts in Medicine

Bayesian SRMA of 3 RCTs showed a high prob (94-98.6%) that fluvoxamine is associated with reduced risk of hospitalization for outpatients with #COVID19, (RR 0.75). @DrEmilyMcD @DrToddLee @simonevigod @AngelaReiersen @boulware_dr https://t.co/ctMKzBDbzP

— JAMA Network Open (@JAMANetworkOpen) April 6, 2022

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines.

7 Apr, 2022 | 10:00h | UTC

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines –
European Centre for Disease Prevention and Control

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

Commentary on Twitter (thread – click for more)

#JustPublished!#ECDC and @EMA_News issue advice on fourth doses of mRNA #COVID19 vaccines.

Read the full joint statement: https://t.co/hBuOlrfKOD pic.twitter.com/aO5vSyYvTk

— ECDC (@ECDC_EU) April 6, 2022

Pragmatic RCT: In outpatients with Covid-19, the addition of pulse oximetry for monitoring did not improve outcomes compared to subjective assessments of dyspnea alone.

7 Apr, 2022 | 09:58h | UTC

Pulse Oximetry for Monitoring Patients with Covid-19 at Home — A Pragmatic, Randomized Trial – New England Journal of Medicine

Commentary on Twitter

A potential practice changer by @kit_delgadoMD et al in NEJM today.

At-home pulse oximeters did NOT improve outcomes.

Important to focus on things that help.

If these devices don't help, then we shouldn't routinely advise them.

Super interesting work.https://t.co/VDDyRLw7ba

— Jeremy Faust MD MS (ER physician) (@jeremyfaust) April 6, 2022

RCT: Among patients with complicated urinary tract infection, oral Tebipenem Pivoxil Hydrobromide was noninferior to intravenous Ertapenem and showed a similar safety profile.

7 Apr, 2022 | 09:53h | UTC

Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

For complicated UTI or acute pyelonephritis, oral tebipenem pivoxil hydrobromide noninferior to IV ertapenem and has a similar safety profile. https://t.co/FRDMQOD0Pn pic.twitter.com/GFQz7SlciX

— NEJM (@NEJM) April 6, 2022

Randomized, sham-controlled trial: Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs.

7 Apr, 2022 | 09:49h | UTC

Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial – The Lancet (link to abstract – $ for full-text)

Commentary: Three-year trial of SPYRAL HTN-ON MED shows blood pressure reductions – MedicalXpress

Systematic Review: Renal denervation may have a modest effect in improving 24h ambulatory blood pressure monitoring (reduction in SBP by 5.29 mmHg and DBP by 3.75 mmHg) but does not improve major cardiovascular outcomes and renal function.

M-A: Renal denervation for hypertension is associated with a modest reduction in ambulatory blood pressure control (3.61 mm Hg reduction in ambulatory systolic BP and 1.85 mm Hg reduction in ambulatory diastolic BP).

#ACC21 – RCT: Among patients with resistant hypertension, ultrasound renal denervation resulted in a modest improvement in systolic BP (–4.5 mm Hg) vs. sham procedure.

Meta-Analysis: Sham-Controlled Randomized Trials of Catheter-Based Renal Denervation in Patients with Hypertension

Commentary on Twitter

Renal denervation could provide an adjunctive treatment modality in the management of patients with #hypertension, suggests trial assessing long-term efficacy & safety in the presence of antihypertensive drugs: https://t.co/45ojbyhQp3 pic.twitter.com/eg6CXGDGCE

— The Lancet (@TheLancet) April 6, 2022

Perspective | Studying severe long COVID to understand post-infectious disorders beyond COVID-19.

7 Apr, 2022 | 08:45h | UTC

Studying severe long COVID to understand post-infectious disorders beyond COVID-19 – Nature Medicine

Review: Post-acute COVID-19 syndrome.

ESCMID rapid guidelines for assessment and management of long COVID.

ERS statement on Long COVID-19 follow-up.

Proposed subtypes of long-Covid and their respective potential therapies.

EuGMS Guidance: Management of post-acute COVID-19 patients in geriatric rehabilitation.

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play.

Review | Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus.

The pathogenesis and long-term consequences of Covid-19 cardiac injury: state-of-the-art review.

COVID-19 infections increase risk of heart conditions up to a year later, study finds.

Commentary from the author on Twitter (thread – click for more)

1/ HGE (https://t.co/VMUVMAo1bJ) position paper on #LongCOVID #PACS . By focusing on the most severe patients, w severe organ damage/dysfunction following mild/moderate #COVID19 – we will search for genetic and immunological mechanisms of disease https://t.co/dZQPEoNkhl pic.twitter.com/tgblk7oFQG

— Petter Brodin (@BrodinPetter) April 5, 2022

Major burns: part 2. Anesthesia, intensive care and pain management.

7 Apr, 2022 | 07:59h | UTC

Major burns: part 2. Anaesthesia, intensive care and pain management – BJA Education

Expert Consensus: Stepwise diagnostic approach for patients with uveitis.

7 Apr, 2022 | 07:53h | UTC

Step-wise diagnostic approach for patients with uveitis – Experts consensus in Taiwan – Journal of Microbiology, Immunology and Infection

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

6 Apr, 2022 | 10:59h | UTC

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel – New England Journal of Medicine

Commentary: Mixed Bag for Fourth Dose of Pfizer Vaccine vs Omicron— Real-world data show less infection and severity, but long-term benefit less clear – MedPage Today (free registration required)

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

Commentary on Twitter

Just published @NEJM
4th dose vaccine protection in >620,000 people vs 3-doses in >620,000, all age 60+, Omicron wave, Israel
—4-fold lower rate of severe disease, no waning at 6 weeks
—2-fold lower rate of infection, rapidly wanedhttps://t.co/g8uGMXGHD6 pic.twitter.com/D7WHywTI1j

— Eric Topol (@EricTopol) April 5, 2022

M-A: Risk of recurrence in women with venous thromboembolism related to estrogen-containing contraceptives.

6 Apr, 2022 | 10:55h | UTC

Risk of recurrence in women with venous thromboembolism related to estrogen-containing contraceptives: Systematic review and meta-analysis – Journal of Thrombosis and Haemostasis

Review and M-A: pulmonary rehabilitation for Post-Covid.

6 Apr, 2022 | 10:42h | UTC

Study 1: The effectiveness of pulmonary rehabilitation for Post-COVID symptoms: A rapid review of the literature – Respiratory Medicine

Study 2: Effect of Pulmonary Rehabilitation for Patients With Post-COVID-19: A Systematic Review and Meta-Analysis – Frontiers in Medicine

Global, regional, and national trends in opioid analgesic consumption from 2015 to 2019.

6 Apr, 2022 | 10:49h | UTC

Global, regional, and national trends in opioid analgesic consumption from 2015 to 2019: a longitudinal study – The Lancet Public Health

News Release: Global disparities persist in opioid painkiller access – University College London

Invited Commentary: Closing the global pain divide: balancing access and excess – The Lancet Public Health

Commentary on Twitter (article and images under a Creative Commons Attribution (CC BY 4.0 license)

Just Out @TheLancetPH 🚨
Global #opioids consumption increased from 2015 to 2019‼️#Disparities in opioid💊consumption remained, indicating potential inadequate access to essential pain relief in countries with low consumption🌐https://t.co/bkcdgLy3ZP pic.twitter.com/RUGl1gbiTw

— Gil Morgan, MD (@weoncologists) April 1, 2022